Sanofi Takes A Multipronged Approach To Maintaining Its Dividend Performance

  • Sanofi faces declining revenue from its diabetes and cardiovascular segments.
  • The company looks to make up for the decline by growing its vaccine segment.
  • Sanofi is also actively pursuing mergers and undertakes hiving off its non-core businesses.

By S.Mitra, MBA (ISB)

Sanofi SA (NYSE:SNY) is one of the pharma sector stalwarts which not only has a strong track record of regular dividend payments but also has an attractive dividend yield rate. The stock is currently trading close to its 52-week high of $50.24 and still gives a yield of 3.39 percent. Further, Sanofi's stock has posted strong price growth in the past 12 months. The momentum seems to come from the active approach taken by the company management which is strategically growing its business through a combination of organic growth, M&As and divestiture, not to mention the litigious route against growing competition from generics.

The full post is available to investor members only. Subscribe here.